BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases ​of patients' hip joint slipping out of ‌place, the drugmaker said on Monday, sending its shares down 4%.

New results demonstrate early VOXZOGO treatment leads to durable and sustained improvements in skeletal growth-related health outcomes, including proportionality, arm span and body mass index, building on over 10,000 patient-years of data   VOXZOGO is the only approved treatment for children with achondroplasia starting at birth and has the most extensive published clinical evidence, including in measures beyond growth, among all achondroplasia treatments SAN RAFAEL, Calif., March 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive new data from studies of VOXZOGO ®  (vosoritide) in children with achondroplasia in ongoing clinical trials and real-world studies.

Dimensional Fund Advisors LP grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 42.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,245,186 shares of the biotechnology company's stock after acquiring an additional 671,566 shares during the quarter. Dimensional

BioMarin Pharmaceutical Inc. (BMRN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.

BioMarin Pharmaceutical Inc. (BMRN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Fisher Asset Management LLC lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 134.2% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 31,726 shares of the biotechnology company's stock after purchasing an additional 18,181 shares during the quarter. Fisher Asset Management

BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older.